HER2 Low Cancers Market: Epidemiology, Therapies, Companies, DelveInsight

Additionally, Dragonfly Therapeutics is advancing DF1001, a dual NK and T-cell engager designed for heavily pretreated HER2-low cancer patients, representing an innovative immunotherapy strategy.

In 2024, Japan reported approximately 15,000 cases of HER2-low urothelial carcinoma eligible for targeted therapy interventions.

Overall, the HER2-low cancer landscape is poised for substantial expansion, driven by an advancing pipeline, personalized treatment approaches, and the increasing global burden of cancer.

Leading companies such as Daiichi Sankyo and AstraZeneca, RemeGen and Pfizer (Seagen), Gilead Sciences, Duality Biologics and BioNTech, Immutep, Merck, Bliss Biopharmaceutical (Hangzhou), Zymeworks, Jazz Pharmaceuticals, ALX Oncology, Dragonfly Therapeutics, and others are actively developing innovative therapies to enhance the HER2 Low Cancers treatment ecosystem.

Prominent HER2 Low Cancers therapies include ENHERTU, DATROWAY (datopotamab deruxtecan), AIDIXI (disitamab vedotin), TRODELVY (sacituzumab govitecan), DB-1303, BNT323 (trastuzumab pamirtecan), Eftilagimod alpha (IMP321), Ifinatamab deruxtecan, BB-1701, ZIIHERA (zanidatamab), and others.

HER2 Low Cancers Overview

HER2 is a transmembrane tyrosine kinase receptor encoded by the ERBB2 gene and plays a central role in regulating cellular proliferation, differentiation, and survival. It belongs to the epidermal growth factor receptor (EGFR) family and is assessed through molecular diagnostic techniques such as immunohistochemistry (IHC) to measure protein expression and fluorescence in situ hybridization (FISH) to evaluate gene amplification. HER2-low tumors are characterized by an IHC score of 1+ or 2+ without gene amplification (FISH-negative or ISH-negative).

HER2/neu signaling occurs predominantly via the MAPK and PI3K pathways, contributing to oncogenesis when dysregulated. HER2 expression is observed across various malignancies, including breast, colorectal, ovarian, endometrial, bladder, gastric, and biliary tract cancers, with breast cancer being the most common.

The introduction of next-generation antibody-drug conjugates (ADCs) has significantly transformed the therapeutic paradigm for HER2-low tumors. ENHERTU, for instance, integrates a HER2-targeted monoclonal antibody with a potent topoisomerase I inhibitor, enabling precise delivery of cytotoxic therapy to HER2-expressing cancer cells.

HER2 Low Cancers Market Outlook

Therapeutic strategies for HER2-low cancers, including gastric, endometrial, and other solid tumors, are rapidly advancing as scientific insights into HER2 biology continue to evolve. Traditional options such as monoclonal antibodies and small-molecule tyrosine kinase inhibitors (TKIs) have demonstrated limited efficacy in tumors with low HER2 expression, creating opportunities for innovative targeted approaches.

Discover how the HER2 Low Cancers market is expanding in the coming years - https://www.delveinsight.com/report-store/her2-low-cancers-market-forecast?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr